Jiang K, Liu M, Zhao X, Wang S, Ling Y, Qiao L
Eur J Clin Pharmacol. 2025; .
PMID: 40080137
DOI: 10.1007/s00228-025-03820-y.
Alonso-Ron C, Vethencourt A, Gonzalez-Suarez E, Oruezabal R
Cancers (Basel). 2025; 17(4).
PMID: 40002228
PMC: 11853049.
DOI: 10.3390/cancers17040633.
Cherukuri P, Tayyeb M, Gaddameedi S, Du D, Meghal T
World J Clin Oncol. 2025; 16(2):97823.
PMID: 39995559
PMC: 11686565.
DOI: 10.5306/wjco.v16.i2.97823.
Passariello M, Manna L, Rapuano Lembo R, Yoshioka A, Inoue T, Kajiwara K
Cell Death Discov. 2025; 11(1):58.
PMID: 39929828
PMC: 11811032.
DOI: 10.1038/s41420-025-02329-8.
Schaub J, Tang S
Clin Exp Med. 2025; 25(1):43.
PMID: 39888507
PMC: 11785663.
DOI: 10.1007/s10238-024-01546-2.
Targeting ferroptosis: a promising approach for treating lung carcinoma.
Wu Z, Zhang Y, Zhong W, Wu K, Zhong T, Jiang T
Cell Death Discov. 2025; 11(1):33.
PMID: 39875356
PMC: 11775225.
DOI: 10.1038/s41420-025-02308-z.
From Pioneering Discoveries to Innovative Therapies: A Journey Through the History and Advancements of Nanoparticles in Breast Cancer Treatment.
Basingab F, Alshahrani O, Alansari I, Almarghalani N, Alshelali N, Alsaiary A
Breast Cancer (Dove Med Press). 2025; 17:27-51.
PMID: 39867813
PMC: 11761866.
DOI: 10.2147/BCTT.S501448.
Harnessing the tumor microenvironment: targeted cancer therapies through modulation of epithelial-mesenchymal transition.
Glaviano A, Lau H, Carter L, Lee E, Lam H, Okina E
J Hematol Oncol. 2025; 18(1):6.
PMID: 39806516
PMC: 11733683.
DOI: 10.1186/s13045-024-01634-6.
Revolutionizing cancer treatment: the rise of personalized immunotherapies.
Fayyaz A, Haqqi A, Khan R, Irfan M, Khan K, Reiner Z
Discov Oncol. 2024; 15(1):756.
PMID: 39692978
PMC: 11655907.
DOI: 10.1007/s12672-024-01638-1.
A surprising complete response to cadonilimab in a primary metastatic cervical cancer: a case report.
Yu H, Lin J, Chen J, Chen L, Zou J, Liu B
Front Immunol. 2024; 15():1494138.
PMID: 39660134
PMC: 11628523.
DOI: 10.3389/fimmu.2024.1494138.
Potential predictive biomarkers in antitumor immunotherapy: navigating the future of antitumor treatment and immune checkpoint inhibitor efficacy.
Yin X, Song Y, Deng W, Blake N, Luo X, Meng J
Front Oncol. 2024; 14:1483454.
PMID: 39655071
PMC: 11625675.
DOI: 10.3389/fonc.2024.1483454.
Tumor microenvironment and cancer metastasis: molecular mechanisms and therapeutic implications.
Biray Avci C, Bagca B, Nikanfar M, Takanlou L, Takanlou M, Nourazarian A
Front Pharmacol. 2024; 15:1442888.
PMID: 39600368
PMC: 11588459.
DOI: 10.3389/fphar.2024.1442888.
Therapeutic Landscape of FOXM1 in Triple-Negative Breast Cancer and Aggressive Solid Cancers.
Dilmac S, Hamurcu Z, Ozpolat B
Cancers (Basel). 2024; 16(22).
PMID: 39594778
PMC: 11593102.
DOI: 10.3390/cancers16223823.
Single-cell sequencing unveils mitophagy-related prognostic model for triple-negative breast cancer.
Ding P, Pei S, Qu Z, Yang Y, Liu Q, Kong X
Front Immunol. 2024; 15:1489444.
PMID: 39559367
PMC: 11570810.
DOI: 10.3389/fimmu.2024.1489444.
Overcoming immunosuppression in cancer: how ketogenic diets boost immune checkpoint blockade.
Stefan V, Weber D, Lang R, Kofler B
Cancer Immunol Immunother. 2024; 74(1):23.
PMID: 39537934
PMC: 11561221.
DOI: 10.1007/s00262-024-03867-3.
Prognostic biomarkers for immunotherapy in esophageal cancer.
Tong X, Jin M, Wang L, Zhang D, Yin Y, Shen Q
Front Immunol. 2024; 15:1420399.
PMID: 39403382
PMC: 11471503.
DOI: 10.3389/fimmu.2024.1420399.
Resistance Management for Cancer: Lessons from Farmers.
Seyedi S, Harris V, Kapsetaki S, Narayanan S, Saha D, Compton Z
Cancer Res. 2024; 84(22):3715-3727.
PMID: 39356625
PMC: 11565176.
DOI: 10.1158/0008-5472.CAN-23-3374.
CDK6 as a Biomarker for Immunotherapy, Drug Sensitivity, and Prognosis in Bladder Cancer: Bioinformatics and Immunohistochemical Analysis.
Zhao X, Yu X, Li W, Chen Z, Niu T, Weng X
Int J Med Sci. 2024; 21(12):2414-2429.
PMID: 39310261
PMC: 11413897.
DOI: 10.7150/ijms.101043.
Blockade of CCR5 T Cell Accumulation in the Tumor Microenvironment Optimizes Anti-TGF-β/PD-L1 Bispecific Antibody.
Yi M, Li T, Niu M, Wu Y, Zhao B, Shen Z
Adv Sci (Weinh). 2024; 11(43):e2408598.
PMID: 39303165
PMC: 11578335.
DOI: 10.1002/advs.202408598.
Unveiling promising targets in gastric cancer therapy: A comprehensive review.
Li W, Wei J, Cheng M, Liu M
Mol Ther Oncol. 2024; 32(3):200857.
PMID: 39280587
PMC: 11396074.
DOI: 10.1016/j.omton.2024.200857.